Deplatt 75 mg FC tablets
PDF Leaflet Revision Date: 19 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of atherosclerotic events in patients with symptomatic atherosclerotic disease.
Dosage (summary)
75 mg once daily.
Onset of Action / Duration
Onset: 1 day, Duration: 7-10 days.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy and breastfeeding.
Key Drug Interactions
- Warfarin
- Aspirin
- Heparin
- Thrombolytics
- NSAIDs
Contraindications
- Hypersensitivity to clopidogrel
- Active bleeding
- Severe liver impairment
- Thrombocytopenia
Common side effects
- Gastrointestinal haemorrhage
- Epistaxis
- Bruising
- Thrombocytopenia
Counselling Points
- Report unusual bleeding
- Inform healthcare providers before surgery
- Take with or without food
Serious warnings
- Risk of Thrombotic Thrombocytopenic Purpura (TTP)
- Increased bleeding risk
Important Disclaimer
The Deplatt 75 mg FC tablets professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
